BRO — Brown & Brown, Inc.

Recent sentiment is cautious/neutral: Q2 2026 revenue and adjusted EPS missed consensus, organic revenue declined 0.7% YoY, and the departure of P. Barrett Brown added leadership uncertainty. Offsetting that, large institutional buyers like BlackRock added stakes, and the stock has stabilized above its 200-day moving average.

Total revenue has stepped up sharply from ~$1.0B per quarter in 2023 to ~$1.7B in 2026, but the jump is almost entirely M&A-driven, especially the Accession acquisition. Q2 2026 revenue rose 34% YoY, yet core organic revenue fell 0.7%, exposing the lack of underlying growth. Adjusted EBITDAC margin compressed 100bps to 35.7%, and EPS growth has lagged net income due to a ~14% increase in diluted shares. This looks like a cyclical/integration trough rather than a structural collapse, but the next two quarters need to show organic growth reaccelerating.

At 19.7x trailing EPS and 3.5x sales, BRO looks cheap versus its own 5-year averages of 26.7x and 5.2x. Forward P/E on next-year EPS of $4.49 is ~15.9x, but that estimate may embed margin improvements that haven't materialized. The discount is justified given the organic growth stall, but the valuation is more 'fair to cheap' than a deep value trap.

At $71.39, the stock is pricing in continued flat-to-negative organic growth and margin pressure. If organic growth turns positive in Q3/Q4 2026 and Accession synergies show up, the forward earnings power of $4.49 could support double-digit upside. If organic stays negative, the current ~20x trailing multiple may be slightly rich. The market is waiting for evidence of an inflection rather than paying up for potential.

As of 2026-08-27, RSI was 52.3, neutral. Price is essentially flat versus the 20-day SMA (-0.15%), 4.1% above the 50-day, and 2.5% above the 200-day—a range-bound, basing pattern. The stock has recovered from the 52-week low of $53.81 but still hasn't reclaimed the $75-80 zone. A break above $73.50 would be a constructive signal, while a drop below $68 would negate the base.

• Moderating P&C insurance pricing cycle: premium rate increases are slowing, directly pressuring commission-based organic growth.
• Higher cost of capital: BRO's M&A-heavy model relies on debt and equity issuance; expensive capital makes deals less accretive.
• Persistent talent wars and wage inflation in the insurance brokerage industry.
• Florida property insurance exposure remains a regional overhang on risk models.
• AI transformation and technology partnerships (Anthropic, Accenture) could improve margins but carry near-term integration costs.

• Q3 2026 earnings (late October): organic revenue turning positive and EBITDAC margin stabilization would be key confirmations.
• Accession integration milestones and early metrics from AI workflow automation.
• Any new M&A or share buyback announcements that signal management confidence.

• Organic growth remains negative and the broader P&C pricing cycle keeps softening.
• M&A-driven share dilution and debt could continue to weigh on EPS growth.
• Leadership turnover: P. Barrett Brown's resignation may indicate cultural or strategic strain.
• Integration and transformation programs may fail to deliver projected cost savings.

This is not a clear-cut buy, but BRO has de-rated to a P/E roughly 25% below its 5-year average while still generating strong free cash flow (~$1.4B TTM) and maintaining high margins. The key swing factor is whether organic growth reaccelerates. I lean positive because the market appears to be pricing in a permanently impaired growth profile, and the historical valuation suggests some mean reversion if the operational wobble passes.

Applying a 22x P/E multiple to TTM EPS of $3.619—a discount to BRO's 5-year average of 26.7x to reflect negative organic growth, yet above the current 19.7x to reflect strong FCF, high margins, and likely mean reversion—yields $79.62. This is roughly 11% above the current price and the consensus target.